Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Annals of Hematology
Published in: Annals of Hematology 1/2004

01-01-2004 | Case Report

Successful treatment with micafungin of invasive pulmonary aspergillosis in acute myeloid leukemia, with renal failure due to amphotericin B therapy

Authors: T. Yokote, T. Akioka, S. Oka, T. Fujisaka, T. Yamano, S. Hara, M. Tsuji, T. Hanafusa

Published in: Annals of Hematology | Issue 1/2004

Login to get access

Abstract

Invasive aspergillosis is an important factor in the morbidity and mortality of patients suffering from hematologic disorders treated with chemotherapy. Treatment with amphotericin B is often limited because of toxicity, particularly nephrotoxicity. We describe a case of invasive pulmonary Aspergillus fumigatus infection in acute myeloid leukemia with renal failure due to amphotericin B therapy, which responded to treatment with a new antifungal agent, micafungin. Micafungin appears to be an effective and safe therapy for Aspergillus infections with renal failure due to amphotericin B.
Literature
1.
Denning DW (1998) Invasive aspergillosis. Clin Infect Dis 26:781–803PubMed
2.
Dannauoui E, Borel E, Persat F, Piens MA, Picot S (2000) Amphotericin B resistance of Aspergillus terreus in a murine medel of disseminated aspergillosis. J Med Microbiol 49:601–606PubMed
3.
Meunier F (1994) Alternative modalities of administering amphotericin B: current issues. J Infect 28[Suppl 1]:51–6
4.
Fanos V, Catalfi Ll (2000) Amphotericin B-induced nephrotoxicity: a review. J Chemother 12:463–470PubMed
5.
Pretice HG, Caillot D, Dupont B (1999) Oral and intravenous itraconazole for systemic fungal infections in neutropenic haematological patients. Acta Haematol 101:56–62CrossRefPubMed
6.
Cornely OA, Ullmann AJ, Karthaus M (2003) Evidence-based assessment of primary antifungal prophylaxis in patients with hematologic malignancies. Blood 101:3365–3372CrossRefPubMed
7.
Iwamoto T, Sakamoto N, Yamashita M (1993) FR90139, a novel antifungal antibiotic. In: Abstract 371 of the 33rd Intersci Conf Antimicrob Agents Chemother, New Orleans, 27–20 Oct
8.
Ueda S, Tanaka M, Ezaki M (1998) Studies on a novel lipopeptide acylase(FR901379 acylase) from Streptomyces sp. for production of FR179642, a key intermediate of antifungal lipopeptide drug FK 463. In: Abstract F 145 of the 38th Intersci Conf Antimicrob Agents Chemother, San Diego,24–27 Sept
9.
Fromtling RA, Castner J (1998) FK-463. Drugs Future 23:1273–1278
10.
Fromtling RA (2002) Micafungin sodium (FK-463). Drugs Today 38:245–257PubMed
11.
Kohno S, Mitsutake K, Maesaki S, Yasuoka A, Miyazaki T, Kaku M, Koga H, Hara K (1993) An evaluation of serodiagnostic tests in patients with candidemia:beta-D-glucan, mannan, Candida antigen by Cand-Tec and D-arabinitol. Microbiol Immunol 37:207–212PubMed
12.
Obayashi T, Yoshida M, Mori T, Goto H, Yasuoka A, Iwasaki H, Teshima H, Kohno S, Horiuchi A, Ito A (1995) Plasma(1➠3)-beta-D-glucan determination in the diagnosis of invasive deep mycosis and fungal febrile episodes. Lancet 345:17–20PubMed
13.
Warn PA, Morrissey G, Morrissey J, Denning DW (2003) Activity of micafungin (FK463) against an itraconazole-resistant strain of Aspergillus fumigatus and a strain of Aspergillus terrus demonstrating in vivo resistance to Amphotericin B. J Antimicrob Chemother 51:913–919CrossRefPubMed
14.
Pettengell K, Mynhardt J, Kluyts T (2000) A multicentre study of the echinocandin antifungal FK 463 for the treatment of esophageal candidiasis in HIV positive patients. In: Abstract of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Ontario, Canada, Abstract 1104, p 371. American Society for Microbiology, Washington, DC, USA
15.
Seibel NL, Schwartz C, Arrieta A (2000) Phase I study to determine the safety and Pharmacokinetics (PK) of FK463 (Echinocandin) in febrile neutropenic pediatric patients. In: Abstract of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Ontario, Canada, Abstract 18, p 1. American Society for Microbiology, Washington, DC, USA
16.
Kohno S, Masaoka T, Yamaguchi (2001) A multicenter, open label clinical study of FK 463 in patients with deep mycosis in Japan. In: Abstract J-834 of the 41st Intersci Conf Antimicrob Agents Chemother, Chicago, 22–25 Sept
17.
Kontoyiannis DP, Buell D, Frisbee-Hume S (2001) Initial experience with FK463 for the treatment of candidemia in cancer patients. In: Abstract J-1629 of the 41st Intersci Conf Antimicrob Agents Chemother, Chicago 22–25 Sept
18.
Ullmann AJ, Van Burik JA, McSweeney P, Ratanatharathom V, Raymond J, de Morais VL, McGuirk J, Lau W, Facklam D, Koblinger S, Reusch M, Marr K, Patterson TF, Denning DW (2003) An open phase II study of the efficacy of micafungin (FK463) alone and in combination for the treatment of invasive aspergillosis (IA) in adults and children. 13th ECCMID meeting, Glasgow, Scotland, UK
Metadata
Title
Successful treatment with micafungin of invasive pulmonary aspergillosis in acute myeloid leukemia, with renal failure due to amphotericin B therapy
Authors
T. Yokote
T. Akioka
S. Oka
T. Fujisaka
T. Yamano
S. Hara
M. Tsuji
T. Hanafusa
Publication date
01-01-2004
Publisher
Springer-Verlag
Published in
Annals of Hematology / Issue 1/2004
Print ISSN: 0939-5555
Electronic ISSN: 1432-0584
DOI
https://doi.org/10.1007/s00277-003-0736-8

Other articles of this Issue 1/2004

Annals of Hematology 1/2004 Go to the issue

Original Article

Reduced incidence of acute graft versus host disease (GVHD) of the gut in Chinese carriers of Helicobacter Pylori during allogeneic bone marrow transplantation

Original Article

Cryopreservation of mobilized blood stem cells at a higher cell concentration without the use of a programmed freezer

Original Article

Hereditary spherocytosis: identification of several HS families with ankyrin and band 3 deficiency in a population of southwestern Poland

Original Article

Hematopoietic stem cell transplantation for severe aplastic anemia—experience of an institute in Taiwan

Case Report

Possible efficacy of lamivudine treatment to prevent hepatitis B virus reactivation due to rituximab therapy in a patient with non-Hodgkin's lymphoma

Case Report

Successful treatment by selective arterial embolization of severe retroperitoneal hemorrhage secondary to bone marrow biopsy in post-polycythemic myelofibrosis
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits